Clinical Trial Update: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy [Phase 3]

View source ↗

Summary

Reports results of a 26-week extension study of EVP-6124 (encenicline), an alpha-7 nicotinic receptor agonist, as adjunctive pro-cognitive therapy in schizophre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Encenicline (EVP-6124) (encenicline)

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Schizophrenia, Impaired Cognition | Phase 3 | Status: COMPLETED